Mechanisms of resistance in malignant melanoma treated by targeted therapy


MUDr. Ondřej Kodet, Ph.D.

Dermatovenerologická klinika 1. LF UK a VFN, Praha

Anatomický ústav 1. LF UK, Praha

BIOCEV - Biotechnologické a biomedicínské centrum AV a UK, Vestec u Prahy



The emergence of tumor resistance to targeted therapy represents a significant public health problem. Overcoming these mechanisms would lead to a prolonged effect of this form of treatment, which excels at a significantly higher percentage of therapeutic responses than immunotherapy. The key to the development of new drugs that potentiate the effect of BRAF and MEK inhibitors is a detailed mapping of resistance mechanisms. This work points to some mechanisms of epigenetic, genetic and influence of tumor microenvironment. It also points to the influence of the immune system, which offers one way to potentiate the effect of targeted therapy.


Key words

targeted therapy, BRAF and MEK inhibitors, melanoma, BRAF V600E mutation, melanoma microenvironment, check-point inhibitors



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...